<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations and diagnosis of polymyalgia rheumatica
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations and diagnosis of polymyalgia rheumatica
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations and diagnosis of polymyalgia rheumatica
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carlo Salvarani, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francesco Muratore, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth J Warrington, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition characterized clinically by aching and morning stiffness about the shoulders, hip girdle, and neck. It can be associated with giant cell arteritis (GCA, also known as Horton disease, Horton giant cell arteritis, and temporal arteritis); the two disorders may represent different manifestations of a shared disease process.
        </p>
        <p>
         When the diagnosis of PMR is considered, two main issues arise:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         How is the diagnosis established and distinguished from other disorders that can produce similar symptoms?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Does the patient also have GCA?
        </p>
        <p>
        </p>
        <p>
         The major features of PMR, with emphasis on clinical manifestations and diagnosis, will be reviewed here. Issues related to the treatment of PMR and to the diagnosis and treatment of GCA are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8222.html" rel="external">
          "Treatment of polymyalgia rheumatica"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">
          "Clinical manifestations of giant cell arteritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">
          "Diagnosis of giant cell arteritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8240.html" rel="external">
          "Treatment of giant cell arteritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polymyalgia rheumatica (PMR) is almost exclusively a disease of adults over the age of 50, with a prevalence that increases progressively with advancing age. The peak incidence of PMR occurs between ages 70 and 80 [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         PMR is relatively common. The lifetime risk of developing PMR has been estimated at 2.43 percent for women and 1.66 percent for men and is second only to rheumatoid arthritis (RA) as a systemic rheumatic disease in adults [
         <a href="#rid2">
          2
         </a>
         ]. Women are affected two to three times more often than men. Cases of familial aggregation are rare, but recognized [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The annual incidence varies geographically and is highest in Scandinavian countries and in people of northern European descent [
         <a href="#rid4">
          4
         </a>
         ]. In Europe, for example, the incidence rates for the population ≥50 years are highest in northern regions (113 per 100,000 per year in Norway) and much lower in southern areas (13 per 100,000 per year in Italy) [
         <a href="#rid5">
          5,6
         </a>
         ]. In Olmsted County, Minnesota, where the population is predominantly of Scandinavian descent, the incidence is 63.9 per 100,000 per year, with a prevalence of 701 out of 100,000 [
         <a href="#rid7">
          7-9
         </a>
         ]. PMR is distinctly less common in Asian, African American, and Latin American populations, though all racial and ethnic groups can be affected.
        </p>
        <p class="headingAnchor" id="H690915865">
         <span class="h2">
          Association with GCA
         </span>
         <span class="headingEndMark">
          —
         </span>
         PMR is two to three times more common than giant cell arteritis (GCA) and occurs in approximately 50 percent of patients with GCA [
         <a href="#rid10">
          10
         </a>
         ]. The percentage of patients with PMR who experience GCA at some point varies widely in reported series, ranging from roughly 5 to 30 percent [
         <a href="#rid1">
          1,11,12
         </a>
         ]. A figure of 10 percent seems most consistent with clinical practice. PMR can precede, accompany, or follow GCA.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS AND PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cause of polymyalgia rheumatica (PMR) is unknown.
        </p>
        <p>
         In addition to the frequent clinical association between PMR and giant cell arteritis (GCA), there are pathogenic similarities (see
         <a class="medical medical_review" href="/z/d/html/8234.html" rel="external">
          "Pathogenesis of giant cell arteritis"
         </a>
         ). Both PMR and GCA are associated with specific alleles of human leukocyte antigen (HLA) DR4. There is also a sequence polymorphism within the hypervariable region of the HLA-DRB1 gene that maps to the antigen-binding cleft of the HLA-DR molecules, suggesting an important role for antigen selection and presentation. Patients with GCA and PMR share this sequence polymorphism, which is not found in patients with rheumatoid arthritis (RA) [
         <a href="#rid13">
          13
         </a>
         ]. Studies of the immunogenetics of PMR contain somewhat limited numbers and need validation in larger patient cohorts.
        </p>
        <p>
         Other immunologic abnormalities shared by PMR and GCA include a similar distribution of circulating CD4+ T-cell subsets; in both conditions, T helper 17 (Th17) cells are increased and regulatory T (Treg) cells are decreased. The proinflammatory cytokine interleukin (IL) 6 is elevated in the peripheral blood of patients with PMR and GCA and is thought to be responsible for their constitutional manifestations.
        </p>
        <p>
         Evidence of subclinical arterial inflammation, including activated dendritic cells, IL-1, and IL-6 can be detected in the temporal arteries of some patients with PMR who have no clinical evidence of GCA [
         <a href="#rid14">
          14
         </a>
         ]. However, unlike in GCA, interferon gamma-producing T cells are not prominent.
        </p>
        <p>
         Some studies of PMR and GCA have suggested a cyclical pattern in incidence and seasonal variation, implying possible environmental infectious triggers [
         <a href="#rid4">
          4
         </a>
         ]. Results of studies of several viruses as potential triggers have been inconclusive.
        </p>
        <p>
         The term "polymyalgia rheumatica" implies a myopathic process, but the muscle in PMR is histopathologically normal. It is in fact the proximal articular and, in particular, the periarticular structures (bursae and tendons) that are mainly affected in PMR, as has been demonstrated by ultrasonography, magnetic resonance imaging (MRI), computed tomography (CT), and 18F fluorodeoxyglucose (FDG) positron emission tomography (PET) [
         <a href="#rid15">
          15-22
         </a>
         ]. (See
         <a class="local">
          'Imaging findings'
         </a>
         below.)
        </p>
        <p>
         Imaging findings at the shoulders include subdeltoid/subacromial bursitis and biceps tenosynovitis. Bilateral subdeltoid/subacromial bursitis is an imaging hallmark of PMR; a meta-analysis of four ultrasound (US) studies found this abnormality in 66 percent (95% CI 36-87 percent) of patients [
         <a href="#rid23">
          23
         </a>
         ]. At the hips, PET studies have demonstrated increased uptake of 18F FDG at the greater trochanters and ischial processes, attributed to bursitis, iliopectineal and iliopsoas bursitis, and hamstring tendinitis. MRI and PET CT have shown evidence for interspinous bursitis in the cervical and lumbar spine  (
         <a class="graphic graphic_diagnosticimage graphicRef129331" href="/z/d/graphic/129331.html" rel="external">
          image 1
         </a>
         ). Glenohumeral and hip joint effusions are less frequently observed.
        </p>
        <p>
         Upper-extremity symptoms in PMR thus result from biceps tenosynovitis, subdeltoid/subacromial bursitis, cervical interspinous bursitis, and, to a lesser extent, glenohumeral synovitis, while pelvic girdle symptoms arise from involvement of various bursae about the hip, hamstring tendinitis, lumbar interspinous bursitis, and hip synovitis.
        </p>
        <p>
         Additional MRI studies have suggested a potential role for capsular inflammation and involvement of the entheses (the insertions of tendons, ligaments, and capsules) in the pathogenesis of PMR [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
         A synovitis characterized by macrophages and CD4+ T lymphocytes has been described in synovial membranes from involved joints [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4158779065">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polymyalgia rheumatica (PMR) is characterized by symmetrical aching and stiffness about the shoulders, hip girdle, neck, and torso, worst on arising in the morning, of recent onset, in a patient over the age of 50  (
         <a class="graphic graphic_figure graphicRef91846" href="/z/d/graphic/91846.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Onset
         </strong>
         – It is typically a recent, discrete change in musculoskeletal symptoms that prompts the patient with PMR to seek medical attention. The onset can be abrupt, sometimes startlingly so, seeming to occur almost overnight. A story of longstanding stiffness and aching does not suggest a diagnosis of PMR.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pattern of symptoms
         </strong>
         – Bilateral shoulder pain is the presenting manifestation in nearly all patients (70 to 95 percent), while the neck and the hip girdle are involved in approximately 70 and 50 percent of patients, respectively. They can initially be unilateral but soon become symmetrical. Bilateral achiness about the upper arms with limitation of active shoulder abduction is particularly common and often commands the clinical presentation. Pelvic girdle symptoms manifest as pains about the groin and lateral aspects of the hips and are frequently reported as radiating to the posterior aspects of the thighs. As described above, the proximally distributed aching and stiffness represent referred symptoms from the joints and periarticular structures of the shoulders and hips. (See
         <a class="local">
          'Pathogenesis and pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Distal symptoms, generally mild, accompany the characteristic proximal symptomatology in approximately one-half of patients, most commonly at the wrists and metacarpophalangeal joints, and occasionally at the knees, but not the feet and ankles. Carpal tunnel syndromes, due to wrist involvement, can be found in 10 to 15 percent of patients [
         <a href="#rid26">
          26
         </a>
         ]. Occasionally, distal symptoms at the hands and wrists are of explosive onset and exuberant extent. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Morning stiffness and the gel phenomenon
         </strong>
         – Gelling, or stiffness with inactivity, is a hallmark of synovitis in the systemic rheumatic diseases in general, but in PMR, this phenomenon can be notably severe. Morning stiffness in PMR is invariable; its absence excludes a diagnosis of PMR. In untreated PMR, morning stiffness can last into the late morning or afternoon. After inactivity, such as after a longer car ride, stiffness can recur. Nocturnal pain is common.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Functional limitations
         </strong>
         – Proximal stiffness can result in difficulties with activities of daily living, such as pulling on a shirt or coat, hooking a bra in the back, donning socks and shoes, or transferring from the supine or seated position to standing. The intensity of the gelling phenomenon, coupled with proximal stiffness, can be such that patients may require assistance with morning dressing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic signs and symptoms
         </strong>
         – Patients with PMR can experience nonspecific systemic signs or symptoms, including malaise, fatigue, depression, anorexia, weight loss, and low-grade fever. The high spiking fever that can accompany giant cell arteritis (GCA), however, is rare in patients who have only PMR. In general, the occurrence of any fever in suspected PMR should prompt a search for underlying GCA or other pathology, especially infection. (See
         <a class="local">
          'Assessment for GCA'
         </a>
         below and
         <a class="local">
          'Differential diagnosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">
          "Diagnosis of giant cell arteritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2689393334">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute phase reactants are elevated in virtually all patients with PMR. Head-to-head studies of the diagnostic value of the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are few, but in clinical experience, the CRP is a more useful index of inflammation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The traditional laboratory finding in PMR is an elevated ESR, which ranges from mildly to markedly increased. In one study, 20 percent of patients had ESR values over 104 mm/hour [
         <a href="#rid27">
          27
         </a>
         ]. Conversely, several studies have found that in approximately 5 to 20 percent of patients with PMR, the ESR is less than 40 mm/hour [
         <a href="#rid28">
          28-30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The CRP is nearly always elevated in PMR. In two reports, an elevated ESR (greater than 30 mm/hour) was noted in 92 to 94 percent of patients at the time of diagnosis of PMR, while 99 percent of such patients had an increased serum CRP level (greater than 5 mg/L) [
         <a href="#rid27">
          27,31
         </a>
         ]. In another study, only 1.5 percent of patients with clinically diagnosed PMR had an ESR and CRP within normal limits (defined as less than 20 mm/hour and 10 mg/L, respectively) at the time of diagnosis [
         <a href="#rid32">
          32
         </a>
         ]. The range of the CRP in PMR, like the ESR, is wide. A diagnostic cut-off value for elevations of the CRP (ie, below which the diagnosis is ruled out) has not been established, but practically speaking, a normal CRP effectively excludes the diagnosis of PMR.
        </p>
        <p>
        </p>
        <p>
         Other laboratory findings are nonspecific:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A normocytic anemia may be present, and the white blood cell and platelet counts are usually normal, though thrombocytosis can occur as part of a general acute inflammatory response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoantibodies, including rheumatoid factor (RF) and anticyclic citrullinated peptide (anti-CCP) antibodies, are usually negative in PMR, and if positive, an alternative diagnosis of late-onset rheumatoid arthritis (RA) should be considered. On the other hand, it should be borne in mind that approximately 10 percent of the older adult population has a positive RF (usually at a low titer) without evidence of RA.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Imaging findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         As discussed above, characteristic features of periarticular structures (eg, bursitis and tenosynovitis) can be seen on ultrasonography, MRI, and positron emission tomography (PET) (see
         <a class="local">
          'Pathogenesis and pathophysiology'
         </a>
         above), but imaging studies are not required to confirm the diagnosis of PMR. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
         While bilateral subdeltoid/subacromial bursitis is a typical imaging feature of PMR, it is not specific and is seen in patients with other inflammatory diseases (such as RA and spondyloarthritis) and other noninflammatory shoulder pathology [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="local">
          'Pathogenesis and pathophysiology'
         </a>
         above.)
        </p>
        <p>
         However, in patients older than 50 years with new-onset pain and morning stiffness in the shoulders, ultrasound (US) or MRI evidence of bilateral subacromial/subdeltoid bursitis and tenosynovitis of the long head of the biceps, especially if bilateral, can be supportive of the diagnosis of PMR. PET findings include increased fluorodeoxyglucose (FDG) uptake in the shoulders, hips, and spinous processes of the cervical and lumbar spine  (
         <a class="graphic graphic_diagnosticimage graphicRef129331" href="/z/d/graphic/129331.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIAGNOSTIC APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H2452892963">
         <span class="h2">
          Evaluation for PMR
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation of patients with suspected polymyalgia rheumatica (PMR) includes a complete history and physical, as well as selected laboratory testing  (
         <a class="graphic graphic_algorithm graphicRef130045" href="/z/d/graphic/130045.html" rel="external">
          algorithm 1
         </a>
         ). Many features of PMR may predispose the unwary clinician to diagnostic error.
        </p>
        <p class="headingAnchor" id="H3857512014">
         <span class="h3">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial history and physical examination should be comprehensive, with specific attention to the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of stiffness and pain of the hips and shoulders and proximal upper and lower extremities; morning stiffness of more than 45 minutes' duration; joint pain and swelling; disruption of sleep; systemic symptoms, such as fever and weight loss; and symptoms suggestive of giant cell arteritis (GCA), such as new headache, jaw claudication, scalp tenderness, visual change, fever, or cough. (See
         <a class="local">
          'Assessment for GCA'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review of systems to elicit a history that could suggest another disorder to explain the symptoms. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation of comorbidities, especially diabetes mellitus, hypertension, and osteoporosis, which could be adversely impacted by glucocorticoid treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete physical examination to evaluate for signs indicative of comorbidities or alternative diagnoses. The cardiovascular examination should include assessment for asymmetry of blood pressures, abnormalities of the temporal arteries, and vascular bruits, which could point to the presence of GCA. (See
         <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">
          "Diagnosis of giant cell arteritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Detailed musculoskeletal examination to determine range of motion of the axial joints (shoulders and hips), peripheral joints, neck, and low back and to assess for evidence of peripheral synovitis. A few important aspects of the physical examination are as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Joint examination
         </strong>
         – Range of motion about the shoulders, cervical spine, and hips can be limited. Restricted shoulder motion is especially common; a classic finding in PMR is the inability to actively abduct the shoulders past 90 degrees  (
         <a class="graphic graphic_picture graphicRef93422" href="/z/d/graphic/93422.html" rel="external">
          picture 1
         </a>
         ). In approximately one-half of patients, distal findings can be identified. Clinical synovitis can occur at the peripheral joints, especially at the wrists and metacarpophalangeal joints, and is usually mild [
         <a href="#rid26">
          26,32,34,35
         </a>
         ]. Minor knee effusions can be found. The feet and ankles are never affected.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         An unusual manifestation of distal involvement is the puffy edematous hand syndrome, or remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome  (
         <a class="graphic graphic_picture graphicRef91484" href="/z/d/graphic/91484.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef93423" href="/z/d/graphic/93423.html" rel="external">
          picture 3
         </a>
         ). In this presentation, distal symptoms and signs can appear explosively and abruptly and often dominate the clinical situation. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neurologic examination
         </strong>
         – The muscles are normal in PMR, and though patients may complain of subjective weakness, and though the motor examination can be problematic in an older adult who is in pain, careful neurologic evaluation will demonstrate normal muscle strength. Tenderness to muscle palpation is a nonspecific sign, and what tenderness there may be about the shoulders relates to articular or bursal involvement.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3480087599">
         <span class="h3">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory testing should include a complete blood count (CBC) and platelet count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels, and documentation of other tests as a baseline prior to initiation of treatment, including glucose, creatinine, liver function tests, and calcium. Depending upon the patient's symptoms, physical findings, and other diagnoses under consideration, additional testing may be required, including serum thyroid-stimulating hormone (TSH), creatine kinase (CK), vitamin D, rheumatoid factor (RF), and anticyclic citrullinated peptide (anti-CCP) antibodies. Additional laboratory tests may be helpful to exclude other disorders that can mimic the disease in the appropriate clinical setting.
        </p>
        <p class="headingAnchor" id="H2351908010">
         <span class="h3">
          Imaging in selected patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         If there is diagnostic uncertainty, MRI or ultrasound (US) may be helpful to assess whether there is underlying bursitis or other local pathology, such as rotator cuff disease. Plain radiographs are not indicated unless another diagnosis that could be confirmed or excluded by such studies is under consideration. (See
         <a class="local">
          'Imaging findings'
         </a>
         above.)
        </p>
        <p>
         Patients with PMR do not routinely need to be imaged for large vessel vasculitis. However, in selected cases in which concomitant GCA is suspected, an evaluation for GCA with imaging (chest/abdomen) such as magnetic resonance angiography (MRA), CT angiography (CTA), or positron emission tomography (PET) may be indicated (see
         <a class="local">
          'Assessment for GCA'
         </a>
         below). Furthermore, in atypical and difficult cases of suspected PMR, imaging (MRA, CTA, or PET) may help to rule out other diseases that can mimic PMR (such as malignancies and infections) [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         PET scanning has demonstrated underlying vascular involvement in a subset of patients with PMR. Increased fluorodeoxyglucose (FDG) vascular uptake compatible with vasculitis on PET scan has been reported in approximately one-third of consecutive patients with a new diagnosis of PMR [
         <a href="#rid37">
          37
         </a>
         ]. In most patients, vascular uptake was seen in the subclavian arteries, but uptake intensity was less intense than that observed in GCA [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         In a cross-sectional analysis of a prospective cohort of 346 consecutive PMR patients without clinical features of GCA, 23 percent had evidence of subclinical vasculitis at US of the temporal superficial, common carotid, subclavian, and axillary arteries. PMR with subclinical GCA showed a predominant extracranial large vessel pattern of vasculitic involvement, and no consistent predictors of subclinical GCA were found [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         The practical implications of subclinical inflammation of the great vessels in PMR is unclear, and further studies are needed to determine whether the findings on imaging are of prognostic or therapeutic consequence [
         <a href="#rid39">
          39
         </a>
         ]. It is unusual for patients with PMR without clinical features of GCA (ie, "pure" PMR) to develop severe cranial ischemic complications such as blindness and stroke at diagnosis and large vessel stenoses or aneurysms during follow-up [
         <a href="#rid40">
          40
         </a>
         ]. However, close observation should be maintained over the entire course of the disease, since typical features of cranial GCA, including ischemic events, may develop during follow-up in these patients [
         <a href="#rid41">
          41
         </a>
         ]. Furthermore, isolated aortitis has been occasionally found at aneurysm surgery in patients with a history of "pure" PMR [
         <a href="#rid42">
          42
         </a>
         ]. Although in our clinical practice we do not treat patients with "pure" PMR who are found to have asymptomatic large vessel involvement on imaging with the higher dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         used for GCA, and we do not recommend imaging follow-up, this is a controversial area, since patients with PMR and large vessel involvement were included in GCA clinical trials and treated as GCA [
         <a href="#rid43">
          43
         </a>
         ]. However, evidence that higher prednisone doses are able to prevent the development of vascular damage, in particular of the ascending aorta aneurysm, and of late cranial GCA is lacking. (See
         <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">
          "Clinical manifestations of giant cell arteritis", section on 'Large vessel involvement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Assessment for GCA
         </span>
         <span class="headingEndMark">
          —
         </span>
         A clinical assessment for the presence of giant cell arteritis (GCA) is a key consideration in the evaluation of the patient with suspected or diagnosed PMR.
        </p>
        <p>
         All patients with PMR should be counseled about symptoms that could suggest GCA, especially new-onset headache, visual impairment, or jaw pain with mastication, and instructed to notify the clinician promptly if such symptoms arise. At presentation and at each follow-up visit, patients with PMR should be assessed for symptoms or physical findings referable to GCA, as GCA can manifest at any point during the clinical course of PMR, at presentation, during treatment with glucocorticoids, or after treatment has been discontinued. (See
         <a class="local">
          'Association with GCA'
         </a>
         above.)
        </p>
        <p>
         Clinically, patients with "pure" PMR lack the classic findings of GCA, such as temporal artery tenderness, headache, jaw pain, visual symptoms, and other evidence of ischemia (eg, arm claudication). In the absence of these symptoms or signs, we do not routinely pursue temporal artery biopsy or large imaging for GCA. However, in selected cases of PMR that incur repeated relapses, have persistently increased acute phase reactants, and appear relatively resistant to glucocorticoids, an evaluation for GCA with large vessel imaging may be indicated [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Risk factors for the clinical expression of GCA in patients with PMR have not been clearly established. In patients on active treatment with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , the persistence of constitutional symptoms (such as fever) or significantly elevated acute phase reactants warrants consideration for underlying GCA or an alternative diagnosis.
        </p>
        <p>
         A positive temporal artery biopsy in PMR patients with no symptoms of GCA has been described but is rare [
         <a href="#rid32">
          32,44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H105400399">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no pathognomonic test or established diagnostic criteria for PMR. We use the presence of all of the following empirically formulated criteria for the clinical diagnosis of PMR when another disease to explain the findings is not present  (
         <a class="graphic graphic_algorithm graphicRef130045" href="/z/d/graphic/130045.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid34">
          34,45-47
         </a>
         ] (see
         <a class="local">
          'Differential diagnosis'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age 50 years or older at disease onset.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bilateral shoulder and/or pelvic girdle aching (lasting longer than 45 minutes) persisting for at least two weeks. The stiffness should involve at least two of the following three areas: neck or torso, shoulders or proximal regions of the arms, and hips or proximal aspects of the thighs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated acute phase reactants (eg, ESR and/or CRP).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid resolution of symptoms with low-dose glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         15 to 25 mg/day or its equivalent). The lack of response to initial therapy strongly suggests an alternative diagnosis (see
         <a class="local">
          'Differential diagnosis'
         </a>
         below). Symptomatic improvement with low-dose glucocorticoid treatment can also be seen in patients with rheumatoid arthritis (RA), psoriatic arthritis, and other inflammatory arthritides.
        </p>
        <p>
        </p>
        <p>
         The International PMR Classification Criteria Group, endorsed by the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism), endorse a stepwise approach for the diagnosis of PMR, which is also consistent with our approach [
         <a href="#rid48">
          48,49
         </a>
         ].
        </p>
        <p>
         Classification criteria for PMR have been proposed by EULAR and the ACR but should not be used as diagnostic criteria  (
         <a class="graphic graphic_table graphicRef129333" href="/z/d/graphic/129333.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid50">
          50,51
         </a>
         ]. The proposed criteria are designed as a research tool to differentiate PMR from other conditions and are not intended for the diagnosis of an individual patient [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         In atypical presentations, such as patients with asymmetric symptoms or with minimally elevated acute phase reactants, establishing the diagnosis is more difficult [
         <a href="#rid28">
          28-30,52
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In younger patients, inflammatory rheumatic diseases that can mimic PMR warrant careful consideration of other diagnoses. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms can be asymmetric early in disease, beginning in one shoulder or hip, but soon become bilateral.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As noted above, a small percentage of patients with bona fide PMR have lower ESRs at the time of diagnosis. Although there is less published experience with use of CRP testing to establish the diagnosis of PMR, an elevated serum CRP (above the upper limit of normal for the testing laboratory) can serve as a criterion for PMR. A normal or modestly elevated ESR by itself should not deter consideration of a diagnosis of PMR in the appropriate clinical setting, but the combination of a normal ESR plus a normal CRP renders the diagnosis much less likely. (See
         <a class="local">
          'Laboratory findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several disorders can mimic PMR  (
         <a class="graphic graphic_table graphicRef129332" href="/z/d/graphic/129332.html" rel="external">
          table 2
         </a>
         ). The most challenging consideration in the differential diagnosis of PMR is seronegative RA presenting in older adults. A variety of other disorders can usually be easily distinguished clinically from PMR [
         <a href="#rid52">
          52-54
         </a>
         ]. Limited laboratory testing may be helpful depending on the specific clinical presentation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rheumatoid arthritis
         </strong>
         – In younger patients in their early 50s, especially those with some degree of peripheral arthritis, the possibility of classic, seropositive RA must be considered. In these situations, measurement of RF and antibodies to anti-CCP is mandatory. Patients with RA commonly have symmetric polyarthritis of the small joints of the hands and feet, which is persistent and only partially responsive to low doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         . The presence of joint erosions differentiates RA from PMR. PMR-related peripheral arthritis is nonerosive, seronegative, and highly responsive to low doses of glucocorticoids [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7502.html" rel="external">
          "Clinical manifestations of rheumatoid arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7520.html" rel="external">
          "Use of glucocorticoids in the treatment of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is, however, considerable overlap between PMR and seronegative RA in older adults who present with peripheral synovitis. Follow-up is often needed to establish the correct diagnosis, and in up to 30 percent of patients initially diagnosed with PMR, the disease is eventually reclassified as "late-onset" or "elderly onset" RA [
         <a href="#rid55">
          55
         </a>
         ]. The following are illustrative:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a report of 159 patients with PMR, seronegative RA, or features of both, who were followed for at least 30 months, recurrent synovitis was observed in 57 patients [
         <a href="#rid56">
          56
         </a>
         ]. During follow-up, 20 of the 57 patients had episodes of symptoms and signs consistent with PMR and, on other occasions, those resembling RA. All patients responded to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         . Twenty-four of the patients later developed GCA: 19 had been given the diagnosis of PMR and 5 of RA. (See
         <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">
          "Diagnosis and differential diagnosis of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A prospective study including 116 patients found that after one year of follow-up, the diagnosis was changed to RA in 20 percent of patients initially diagnosed with PMR [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         No clinical and laboratory findings consistently separate PMR from seronegative RA in the older adult; ultimately, the differentiation between the two rests on vigilant clinical follow-up [
         <a href="#rid57">
          57,58
         </a>
         ]. Measurement of anti-CCP will identify the older adult with classically seropositive RA [
         <a href="#rid59">
          59
         </a>
         ]. The presence of joint erosions on plain radiographs at diagnosis or their development during follow-up differentiates RA from PMR [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In situations where PMR cannot be clinically distinguished from seronegative RA, we treat with glucocorticoids in the doses used for PMR and carefully monitor the clinical response. It can take several months to differentiate PMR from rheumatoid disease with certainty. Patients who respond well are continued on this treatment regimen, and glucocorticoids are tapered accordingly. Treatment for RA should be instituted if symptoms of arthritis respond incompletely or evolve into a pattern more characteristic of RA. (See
         <a class="medical medical_review" href="/z/d/html/8222.html" rel="external">
          "Treatment of polymyalgia rheumatica"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          RS3PE syndrome
         </strong>
         – The RS3PE syndrome refers to
         <strong>
          r
         </strong>
         emitting
         <strong>
          s
         </strong>
         eronegative
         <strong>
          s
         </strong>
         ymmetrical
         <strong>
          s
         </strong>
         ynovitis with
         <strong>
          p
         </strong>
         itting
         <strong>
          e
         </strong>
         dema, also described as the puffy edematous hand syndrome or distal extremity swelling with pitting edema  (
         <a class="graphic graphic_picture graphicRef93423" href="/z/d/graphic/93423.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid60">
          60
         </a>
         ]. In this syndrome, distal symptoms and signs, often of sudden onset, are pronounced, though careful musculoskeletal examination will usually also disclose some degree of limited range of motion about the shoulders. Swelling, which is usually pitting, extends over the dorsa of the wrists to the metacarpophalangeal joints, producing the appearance of a "boxing glove," with limited range of motion of the hands and wrists. Assays for RF and anti-CCP are negative [
         <a href="#rid61">
          61
         </a>
         ]. US and MRI demonstrate prominent extensor tenosynovitis of the extensor tendon of the forearms and hands, with lesser amounts of flexor tenosynovitis and synovitis of the metacarpophalangeal and proximal interphalangeal joints [
         <a href="#rid62">
          62
         </a>
         ]. An association with solid tumors and hematologic disorders has also been reported, but in clinical practice such an occurrence is rare [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multifocal local musculoskeletal disease
         </strong>
         – Symptoms and signs at the shoulders in PMR can be similar to those that result from subacromial/subdeltoid bursitis without PMR or from bilateral rotator cuff tendinitis. Local pathology of this sort is common in older adults, can be bilateral, and, when combined with symptoms and signs of degenerative disc disease at the cervical spine and/or osteoarthritis at the hips, could suggest PMR. In such patients, however, morning stiffness is brief, constitutional symptoms are absent, and the acute phase reactants are not elevated. (See
         <a class="local">
          'Imaging findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone disease
         </strong>
         – The differential diagnosis of diffuse achiness in an older adult includes osseous disease. Multiple myeloma can present with bone pain and an elevated ESR, thereby simulating PMR. Such patients can be identified by the presence of a monoclonal protein in the serum or urine (see
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"
         </a>
         ). Widespread skeletal metastases can present with diffuse pain, so details of a prior history of malignancy should not be overlooked. Hyperparathyroidism can present with proximal stiffness and aching, often in older patients, usually in the context of hypercalcemia and elevated parathyroid hormone (see
         <a class="medical medical_review" href="/z/d/html/2029.html" rel="external">
          "Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation"
         </a>
         ). Osteomalacia, with multiple microfractures, can be associated with widespread musculoskeletal pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug-induced myalgias or myositis
         </strong>
         – Statins can be associated with a variety of myopathic syndromes, including statin-related myopathy and myalgias. Explicit myopathy causes weakness and elevations of the serum CK levels, which are not features of PMR. Statin-related myalgias can usually be distinguished from PMR by the absence of prominent morning stiffness and by the lack of proximally and symmetrically distributed symptoms. (See
         <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">
          "Statin muscle-related adverse events"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inflammatory myopathy
         </strong>
         – Patients with dermatomyositis or polymyositis present with symmetric proximal muscle weakness, and shoulder and hip pain is not as prominent as in PMR. Elevated muscle enzymes, abnormal electromyography, abnormal MRI, and evidence of myositis on muscle biopsy establish the diagnosis of an inflammatory myopathy. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fibromyalgia
         </strong>
         – Patients with fibromyalgia experience widespread musculoskeletal pain, stiffness, aching, and fatigue. Although such patients are often younger than 50 years, fibromyalgia can be seen in older patients. Patients with fibromyalgia have symptoms of longstanding duration, in contrast to PMR, where symptoms are of recent, acute, or subacute onset. Physical examination in fibromyalgia discloses no abnormalities, apart from characteristic tender points, and unlike patients with PMR, those with fibromyalgia have a normal ESR, CRP, and hematocrit. (See
         <a class="medical medical_review" href="/z/d/html/5624.html" rel="external">
          "Clinical manifestations and diagnosis of fibromyalgia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – The occurrence of fever in suspected PMR is always of concern and warrants consideration for infection, as endocarditis and other infectious diseases can occasionally mimic PMR. Polyarthralgias occurring in the context of fever and a heart murmur require blood cultures and evaluation for infectious endocarditis (see
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         ). Patients with early, localized, or disseminated Lyme disease can present with nonspecific constitutional symptoms that include myalgias and arthralgias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – Other conditions whose initial presentations can occasionally prompt diagnostic concern for PMR include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Parkinson disease
         </strong>
         – Parkinson disease can present with stiffness in an older adult but is commonly accompanied by abnormalities on neurologic examination, including tremor and rigidity. (See
         <a class="medical medical_review" href="/z/d/html/4904.html" rel="external">
          "Diagnosis and differential diagnosis of Parkinson disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypothyroidism
         </strong>
         – Patients with hypothyroidism can present with aching, stiffness, and arthralgias. Slow relaxation of deep tendon reflexes, a low serum thyroxine (T4) concentration, and an elevated serum TSH concentration are characteristic of hypothyroidism and are not seen in PMR. (See
         <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">
          "Clinical manifestations of hypothyroidism", section on 'Musculoskeletal symptoms'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">
          "Diagnosis of and screening for hypothyroidism in nonpregnant adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Malignancy
         </strong>
         – Though there are rare anecdotes of malignancy presenting with muscle and joint pains that resemble PMR [
         <a href="#rid52">
          52
         </a>
         ], the overall risk of malignancy in PMR is not increased. Contradictory findings have been reported from earlier studies, which identified no such risk, on the one hand, and subsequent studies based on large administrative data sets, which suggested an excess malignancy risk in the first 6 to 12 months after the diagnosis, on the other [
         <a href="#rid65">
          65-67
         </a>
         ]. A population-based cohort study, however, found no difference in the cumulative risk of malignancy after 10 years of follow-up in patients with PMR compared with comparator subjects [
         <a href="#rid68">
          68
         </a>
         ]. A malignancy workup is thus not required for a patient with an uncomplicated presentation of PMR. The presence of atypical clinical features (eg, fever, adenopathy, pulmonary infiltrate), however, must be carefully assessed before a diagnosis of PMR can be endorsed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Myelodysplastic syndromes can be associated with a variety of rheumatologic manifestations, among which are symptoms and signs typical of PMR [
         <a href="#rid69">
          69
         </a>
         ]. The therapeutic response to low-dose glucocorticoids is usually brisk, as in PMR. The finding of leukopenia or thrombocytopenia in a patient with otherwise typical PMR should lead to further hematologic evaluation. (See
         <a class="medical medical_review" href="/z/d/html/5615.html" rel="external">
          "Malignancy and rheumatic disorders", section on 'Malignant diseases with musculoskeletal manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         PMR (and GCA) have been observed in the context of the use of
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         for immunotherapy of malignant melanoma, and cases of PMR have now been seen with the use of other checkpoint inhibitors [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors", section on 'Rheumatologic and musculoskeletal'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vasculitis
         </strong>
         – Vasculitic disorders other than GCA can present with arthralgias and an elevated ESR. In a retrospective study of 86 patients with systemic vasculitis affecting small vessels, 11 (13 percent) were thought to have PMR prior to the recognition of renal involvement [
         <a href="#rid71">
          71
         </a>
         ]. All 11 were found to have antineutrophil cytoplasmic antibodies (ANCA). Clinical and laboratory features that suggest ANCA-associated vasculitis include symptoms of upper respiratory tract involvement, pulmonary hemorrhage, renal disease, neuropathy, and positive ANCA. (See
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Crowned dens syndrome
         </strong>
         – "Crowned dens" refers to the radiologic appearance of the dens resulting from soft-tissue calcifications of the periodontoid tissues, presumably due to hydroxyapatite crystals or calcium pyrophosphate deposition disease. The accompanying clinical syndrome can be acute and severe and include shoulder girdle stiffness, fever, and elevations of the acute phase reactants. Plain films may or may not show calcifications. CT examination of C1-C2 is necessary to confirm the periodontoid localization of calcification  (
         <a class="graphic graphic_diagnosticimage graphicRef94325" href="/z/d/graphic/94325.html" rel="external">
          image 2
         </a>
         ). Symptomatic relief is obtained with nonsteroidal antiinflammatory drugs (NSAIDs) or
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         [
         <a href="#rid72">
          72,73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Spondyloarthropathy
         </strong>
         – Proximal symptoms similar to PMR have been described in occasional patients with late-onset spondyloarthropathy [
         <a href="#rid74">
          74
         </a>
         ], including axial skeletal involvement, oligoarthritis, distal pitting edema, and constitutional symptoms such as fever, anorexia, and weight loss, along with an elevated ESR. In these patients, spondyloarthropathy can be differentiated from PMR by the presence of enthesitis, dactylitis, anterior uveitis, or sacroiliitis on imaging and by a high prevalence of human leukocyte antigen (HLA) B27. (See
         <a class="medical medical_review" href="/z/d/html/7795.html" rel="external">
          "Clinical manifestations and diagnosis of peripheral spondyloarthritis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95962.html" rel="external">
          "Overview of the clinical manifestations and classification of spondyloarthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Depression
         </strong>
         – Depression, which occurs in some patients with PMR, can be associated with weight loss and somatic symptoms, including aching and stiffness. Patients with depression do not have typical proximal aching and protracted morning stiffness. (See
         <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">
          "Unipolar depression in adults: Assessment and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3662868416">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117108.html" rel="external">
          "Society guideline links: Giant cell arteritis and polymyalgia rheumatica"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15532.html" rel="external">
          "Patient education: Polymyalgia rheumatica and giant cell arteritis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/576.html" rel="external">
          "Patient education: Polymyalgia rheumatica and giant cell arteritis (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and epidemiology
         </strong>
         – Polymyalgia rheumatica (PMR) is an inflammatory rheumatologic condition characterized clinically by aching and morning stiffness about the shoulders, hip girdle, neck, and torso. It can be associated with giant cell arteritis (GCA, also known as Horton disease, Horton giant cell arteritis, and temporal arteritis). PMR is almost exclusively a disease of adults over the age of 50; the incidence increases progressively with advancing age. The average age at diagnosis is over 70 years. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Association with GCA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Proximal joint and neck symptoms are worst with inactivity, resulting in nocturnal pain and prominent morning stiffness. Morning stiffness, which can be severe and protracted, is invariable. Symptomatology involving the shoulders and upper arms is especially common and can produce a characteristic clinical finding, that of restricted active range of motion at the shoulders, especially abduction. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Physical examination can demonstrate decreased passive range of motion of the shoulders, neck, and hips. Muscle strength is normal when carefully tested. (See
         <a class="local">
          'History and physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory findings
         </strong>
         – The characteristic laboratory finding is an elevation of the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP; acute phase reactants). The range of these values is wide. The ESR occasionally exceeds 100 mm/hour but can also be less than 40 in a minority (5 to 20 percent) of patients. The CRP is nearly always raised and clinically is more sensitive than ESR for the diagnosis. (See
         <a class="local">
          'Laboratory findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of PMR can be made in patients with the following features, in whom another disease to explain the findings is not present  (
         <a class="graphic graphic_algorithm graphicRef130045" href="/z/d/graphic/130045.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Diagnosis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age 50 years or older at onset of symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bilateral aching and morning stiffness (lasting 45 minutes or more) persisting for at least two weeks and involving at least two of the following three areas: neck or torso, shoulders or proximal regions of the arms, and hips or proximal aspects of the thighs.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elevated acute phase reactants (eg, ESR and/or CRP).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prompt response of symptoms to low-dose glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         15 to 25 mg/day or its equivalent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment for GCA
         </strong>
         – Patients must routinely be monitored for signs and symptoms suggestive of GCA. (See
         <a class="local">
          'Assessment for GCA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Diagnostic evaluation for GCA (temporal artery biopsy, temporal artery ultrasound [US], positron emission tomography [PET], CT scanning) is not required in the absence of signs or symptoms referable to GCA but should be pursued if indicated. (See
         <a class="local">
          'Assessment for GCA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Early seronegative rheumatoid arthritis (RA) can initially be difficult to differentiate from PMR. The differential diagnosis also includes a variety of other disorders that can usually be distinguished from PMR on clinical grounds  (
         <a class="graphic graphic_table graphicRef129332" href="/z/d/graphic/129332.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2643531452">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges William P Docken, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum 1995; 38:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liozon E, Ouattara B, Rhaiem K, et al. Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families. Clin Exp Rheumatol 2009; 27:S89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94. J Rheumatol 1997; 24:1739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doran MF, Crowson CS, O'Fallon WM, et al. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002; 29:1694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowson CS, Matteson EL. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin Arthritis Rheum 2017; 47:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raheel S, Shbeeb I, Crowson CS, Matteson EL. Epidemiology of Polymyalgia Rheumatica 2000-2014 and Examination of Incidence and Survival Trends Over 45 Years: A Population-Based Study. Arthritis Care Res (Hoboken) 2017; 69:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González-Gay MA, García-Porrúa C, Vázquez-Caruncho M, et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999; 26:1326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) 2001; 40:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weyand CM, Hunder NN, Hicok KC, et al. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 1994; 37:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994; 121:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camellino D, Cimmino MA. Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. Rheumatology (Oxford) 2012; 51:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frediani B, Falsetti P, Storri L, et al. Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients. J Rheumatol 2002; 29:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koski JM. Ultrasonographic evidence of synovitis in axial joints in patients with polymyalgia rheumatica. Br J Rheumatol 1992; 31:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantini F, Salvarani C, Niccoli L, et al. Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. J Rheumatol 2004; 31:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macchioni P, Catanoso MG, Pipitone N, et al. Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology (Oxford) 2009; 48:1566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henckaerts L, Gheysens O, Vanderschueren S, et al. Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica-A prospective study of 99 patients. Rheumatology (Oxford) 2018; 57:1908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owen CE, Poon AMT, Lee ST, et al. Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica. Rheumatology (Oxford) 2018; 57:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuge S, Nakatani K, Yoshino K, Koyama T. Diagnosing polymyalgia rheumatica on 18F-FDG PET/CT: typical uptake patterns. Ann Nucl Med 2018; 32:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackie SL, Koduri G, Hill CL, et al. Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. RMD Open 2015; 1:e000100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marzo-Ortega H, Rhodes LA, Tan AL, et al. Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. Arthritis Rheum 2007; 56:3496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meliconi R, Pulsatelli L, Uguccioni M, et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum 1996; 39:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Cantini F, Macchioni P, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 1998; 41:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000; 30:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum 1996; 39:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González-Gay MA, Rodríguez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome. Arch Intern Med 1997; 157:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Proven A, Gabriel SE, O'Fallon WM, Hunder GG. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol 1999; 26:1333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Cantini F, Niccoli L, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005; 53:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996; 35:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantini F, Salvarani C, Olivieri I, et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 2001; 28:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Cantini F, Olivieri I, Hunder GS. Polymyalgia rheumatica: a disorder of extraarticular synovial structures? J Rheumatol 1999; 26:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muratore F, Pazzola G, Pipitone N, Salvarani C. Recent advances in the diagnosis and treatment of polymyalgia rheumatica. Expert Rev Clin Immunol 2016; 12:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blockmans D, De Ceuninck L, Vanderschueren S, et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford) 2007; 46:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Miguel E, Macchioni P, Conticini E, et al. Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica. Rheumatology (Oxford) 2024; 63:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA 2016; 315:2442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muratore F, Pazzola G, Pipitone N, et al. Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica. Clin Exp Rheumatol 2014; 32:S106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narváez J, Estrada P, López-Vives L, et al. Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica. Semin Arthritis Rheum 2015; 45:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang KP, Chowdhary VR, Michet CJ, et al. Noninfectious ascending aortitis: a case series of 64 patients. J Rheumatol 2009; 36:2290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 2017; 377:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez-Valverde V, Sarabia JM, González-Gay MA, et al. Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med 1997; 102:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bird HA, Esselinckx W, Dixon AS, et al. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979; 38:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981; 40:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984; 13:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 2010; 49:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dasgupta B, Hutchings A, Matteson EL. Polymyalgia rheumatica: the mess we are now in and what we need to do about it. Arthritis Rheum 2006; 55:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012; 64:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken) 2015; 67:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks RC, McGee SR. Diagnostic dilemmas in polymyalgia rheumatica. Arch Intern Med 1997; 157:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvarani C, Pipitone N, Versari A, Hunder GG. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 2012; 8:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet 2013; 381:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Healey LA. Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity. J Rheumatol 1992; 19:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caporali R, Montecucco C, Epis O, et al. Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. Ann Rheum Dis 2001; 60:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pease CT, Haugeberg G, Montague B, et al. Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. Rheumatology (Oxford) 2009; 48:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez-Hoyos M, Ruiz de Alegria C, Blanco R, et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 2004; 43:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarty DJ, O'Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 1985; 254:2763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivieri I, Salvarani C, Cantini F. RS3PE syndrome: an overview. Clin Exp Rheumatol 2000; 18:S53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klauser A, Frauscher F, Halpern EJ, et al. Remitting seronegative symmetrical synovitis with pitting edema of the hands: ultrasound, color doppler ultrasound, and magnetic resonance imaging findings. Arthritis Rheum 2005; 53:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibilia J, Friess S, Schaeverbeke T, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE): a form of paraneoplastic polyarthritis? J Rheumatol 1999; 26:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura M, Tokuda Y, Oshiawa H, et al. Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica. J Rheumatol 2012; 39:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol 1993; 20:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol 2002; 29:2143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muller S, Hider SL, Belcher J, et al. Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. Ann Rheum Dis 2014; 73:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfeifer EC, Crowson CS, Major BT, Matteson EL. Polymyalgia Rheumatica and its Association with Cancer. Rheumatology (Sunnyvale) 2015; Suppl 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinosa G, Font J, Muñoz-Rodríguez FJ, et al. Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship? Clin Rheumatol 2002; 21:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrese C, Cappelli LC, Kostine M, et al. Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. RMD Open 2019; 5:e000906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little MA, Nazar L, Farrington K. Polymyalgia rheumatica preceding small-vessel vasculitis: changed spots or misdiagnosis? QJM 2004; 97:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aouba A, Vuillemin-Bodaghi V, Mutschler C, De Bandt M. Crowned dens syndrome misdiagnosed as polymyalgia rheumatica, giant cell arteritis, meningitis or spondylitis: an analysis of eight cases. Rheumatology (Oxford) 2004; 43:1508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uh M, Dewar C, Spouge D, Blocka K. Crowned dens syndrome: a rare cause of acute neck pain. Clin Rheumatol 2013; 32:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivieri I, Garcia-Porrua C, Padula A, et al. Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases. Rheumatol Int 2007; 27:927.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8235 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7880191" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21360492" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19646354" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19790127" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Epidemiology of giant cell arteritis and polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9292797" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2003856" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12180732" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28551169" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27768840" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Epidemiology of Polymyalgia Rheumatica 2000-2014 and Examination of Incidence and Survival Trends Over 45 Years: A Population-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7598301" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10381051" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11709607" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8147928" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8067646" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21565899" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11824948" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1540791" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Ultrasonographic evidence of synovitis in axial joints in patients with polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14705230" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19808693" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29136209" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica-A prospective study of 99 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29121248" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29948622" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Diagnosing polymyalgia rheumatica on 18F-FDG PET/CT: typical uptake patterns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26535139" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17907197" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8670331" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9663479" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10966209" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8849384" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9040299" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10381052" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15696567" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8948307" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11361188" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6982645" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Polymyalgia rheumatica: a 10-year epidemiologic and clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10090155" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Polymyalgia rheumatica: a disorder of extraarticular synovial structures?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27079756" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Recent advances in the diagnosis and treatment of polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17114803" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37129541" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27299619" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24854380" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26186807" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19648309" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Noninfectious ascending aortitis: a case series of 64 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28745999" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Trial of Tocilizumab in Giant-Cell Arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9217613" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/518143" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : An evaluation of criteria for polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7469518" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prognosis and management of polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6729485" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Long-term follow-up of polymyalgia rheumatica: evidence for synovitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19910443" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : BSR and BHPR guidelines for the management of polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16874793" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Polymyalgia rheumatica: the mess we are now in and what we need to do about it.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22389040" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25776731" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Distinctions between diagnostic and classification criteria?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9009973" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Diagnostic dilemmas in polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18640460" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Polymyalgia rheumatica and giant-cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22825731" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Clinical features of polymyalgia rheumatica and giant cell arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23051717" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1629826" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11602472" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18980958" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14970400" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4057484" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10948764" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : RS3PE syndrome: an overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15818642" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Remitting seronegative symmetrical synovitis with pitting edema of the hands: ultrasound, color doppler ultrasound, and magnetic resonance imaging findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9918251" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Remitting seronegative symmetrical synovitis with pitting edema (RS3PE): a form of paraneoplastic polyarthritis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22174210" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8230015" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Cancer in association with polymyalgia rheumatica and temporal arteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12375324" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23842460" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26688777" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Polymyalgia Rheumatica and its Association with Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12189460" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31168414" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15100422" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Polymyalgia rheumatica preceding small-vessel vasculitis: changed spots or misdiagnosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15316123" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Crowned dens syndrome misdiagnosed as polymyalgia rheumatica, giant cell arteritis, meningitis or spondylitis: an analysis of eight cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23392827" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Crowned dens syndrome: a rare cause of acute neck pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17426977" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
